Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Change in Cash (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Change in Cash for 15 consecutive years, with -$6.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash fell 118.34% to -$6.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$219.6 million, a 479.14% decrease, with the full-year FY2024 number at -$148.7 million, down 454.76% from a year prior.
  • Change in Cash was -$6.0 million for Q3 2025 at Usana Health Sciences, up from -$28.2 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $41.0 million in Q4 2022 to a low of -$183.2 million in Q4 2024.
  • A 5-year average of -$15.7 million and a median of -$2.1 million in 2022 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: skyrocketed 438.59% in 2023, then crashed 882.28% in 2024.
  • Usana Health Sciences' Change in Cash stood at -$55.9 million in 2021, then skyrocketed by 173.31% to $41.0 million in 2022, then plummeted by 42.81% to $23.4 million in 2023, then plummeted by 882.28% to -$183.2 million in 2024, then surged by 96.74% to -$6.0 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Change in Cash are -$6.0 million (Q3 2025), -$28.2 million (Q2 2025), and -$2.1 million (Q1 2025).